Among the five genes in the IPS, CTLA4 is an important negative regulator of T cells [35] and can inhibit T cell function via various mechanisms [36,37], which contributed to the clinical development and application of anti-CTLA4 for tumor immunotherapy [38]. Here, CTLA4 is linked to neoplasm.